Catalog No.
YHB91109
Expression system
E. coli
Species
Human
Protein length
Met1-Met188 (G12R)
Predicted molecular weight
48.35 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P01116-2
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for one week. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
c-Ki-ras, RASK2, GTPase KRas, K-Ras 2, c-K-ras, KRAS, Ki-Ras, KRAS2
KRAS mutation status critically determines the clinical outcome of patients with KMT2A-rearranged acute myeloid leukemia., PMID:40530668
Oncogenic stress response mechanisms as new therapeutic targets in cancer treatment: A review., PMID:40527836
Gut sulfide metabolism modulates behavior and brain bioenergetics., PMID:40526718
Molecular landscape of HER2-mutated non-small cell lung cancer in Northeastern Brazil: Clinical, histopathological, and genomic insights., PMID:40526089
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation., PMID:40523897
BRAF V600E mutation associated with papillary high-grade serous ovarian cystadenocarcinoma in a 22q11.2DS patient., PMID:40521346
Anticancer potential of eugenol in hepatocellular carcinoma through modulation of oxidative stress, inflammation, apoptosis, and proliferation mechanisms., PMID:40506614
BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction., PMID:40504949
GCLM lactylation mediated by ACAT2 promotes ferroptosis resistance in KRASG12D-mutant cancer., PMID:40503938
Computational design of conformation-biasing mutations to alter protein functions., PMID:40501788
An Advanced IVB Lung Adenocarcinoma Patient With KRAS Mutations, Benefited From Camrelizumab Combined With Anti-Angiogenic Agents for Therapy: A Case Report., PMID:40488279
Erianin inhibits the proliferation and stemness of pancreatic cancer cells by interacting with MEK1/2., PMID:40484042
Indoleamine 2,3-dioxygenase-1 expression in non-small-cell lung cancer: analyses of prevalence, clinical correlations and prognostic impact in 2 large patient cohorts., PMID:40475772
KRAS/NRAS variants and copy number alterations prognostically stratify patients with sinonasal melanoma., PMID:40474710
Comprehensive morphological, immunohistochemical, and molecular characterization of congenital pulmonary airway malformation (CPAM)., PMID:40473982
RNA processing kinase inhibitors and epigenetic inhibitors in combination with oncology drugs or investigational agents in multi-cell type patient-derived tumor cell line spheroids., PMID:40470182
Retrospective stratified analysis of resistance mechanisms to anti-EGFR therapy in mCRC using tumor tissue samples., PMID:40467730
MAGNET-seq: A tandem PCR and hybrid capture method for enhanced target enrichment., PMID:40465784
Inhibition of NR2F2 restores hormone therapy response to endocrine refractory breast cancers., PMID:40465692
[Genetic and clinical characteristics of children with RAS-mutated juvenile myelomonocytic leukemia]., PMID:40462427
Circulating tumor DNA dynamic variation predicts sotorasib efficacy in KRASp.G12C-mutated advanced non-small cell lung cancer., PMID:40445863
Factors affecting survival prognosis of patients with rectal cancer after neoadjuvant chemoradiotherapy., PMID:40444087
Macrophage activation determines muscle wasting in pancreatic cancer., PMID:40442475
Combination therapy of avutometinib and MRTX1133 synergistically suppresses cell growth by inducing apoptosis in KRASG12D-mutated pancreatic cancer., PMID:40439998
Dauricine Impedes the Tumorigenesis of Lung Adenocarcinoma by Regulating Nrf2 and Reactive Oxygen Species., PMID:40422202
Use of new approach methodology for hepatic safety assessment of covalent inhibitor drug candidates., PMID:40421426
The subcellular distribution of phosphorylated Y-box-binding protein-1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features., PMID:40420381
HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity., PMID:40419509
A novel KRAS exon 2 drop-off digital PCR assay for mutation detection in cell-free DNA of cancer patients., PMID:40413426
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer., PMID:40402502
Genetic and Phenotypic correlates of clinical outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN study., PMID:40396900
Novel Phenoxyacetic Acid (4-Aminophenoacetic Acid) Shikonin Ester Kills KRAS Mutant Colon Cancer Cells via Targeting the Akt Allosteric Site., PMID:40395209
Metformin and chloroquine enhanced the efficacy of cytarabine in acute lymphoblastic leukemia cell lines: a drug repositioning approach., PMID:40360710
Regional distribution of HLA frequencies in the USA: implications for TCR-based therapies., PMID:40360437
Dual inhibition of GTP-bound KRAS and mTOR in lung adenocarcinoma and squamous cell carcinoma harboring KRAS G12C., PMID:40350441
Norepinephrine mediates adrenergic receptor transcription and oncogenic gene expression in pancreatic ductal adenocarcinoma., PMID:40349604
Equalizing prognostic disparities in KRAS-mutated stage III NSCLC patients: addition of durvalumab to combined chemoradiotherapy improves survival., PMID:40349418
Targeting the HER2-ELF3-KRAS axis: a novel therapeutic strategy for KRASG13D colorectal cancer., PMID:40340861
Targeting the SHOC2-RAS interaction in RAS-mutant cancers., PMID:40335703
Distinct roles for the thioredoxin and glutathione antioxidant systems in Nrf2-Mediated lung tumor initiation and progression., PMID:40334547
A comprehensive analysis identified an autophagy-related risk model for predicting recurrence and immunotherapy response in stage I lung adenocarcinoma., PMID:40330698
Shc1 cooperates with Frs2 and Shp2 to recruit Grb2 in FGF-induced lens development., PMID:40327534
RAS gene polymorphisms confer the risk of neuroblastoma in Chinese children from Jiangsu province., PMID:40323475
NMR 1H, 13C, and 15N resonance assignments of the oncogenic Q61R variant of human NRAS in the active, GTP-bound conformation., PMID:40316884
Prognostic Properties of KRAS Gene Mutation Subtypes in Resected Pancreatic Ductal Adenocarcinoma., PMID:40314742
MTMR regulates KRAS function by controlling plasma membrane levels of phospholipids., PMID:40314454
Napsin A as a key prognostic biomarker in spinal metastases of lung cancer: implications for survival and neurological function., PMID:40311196
Cell cycle duration determines oncogenic transformation capacity., PMID:40307557
GENETIC ALTERATIONS IN TUBO-OVARIAN EPITHELIUM DURING OVARIAN NEOPLASIA., PMID:40305800
For research use only. Not for human or drug use.
